Table 2.
Serological and clinical characteristics of the systemic lupus erythematosus cohort.
| In flare | No flare | p | |
|---|---|---|---|
| Serology | |||
| n | 12 | 33 | |
| CRP, median in mg/dl (IQR) | 1.2 (1.7) | 0.4 (1.5) | 0.189a |
| C3, median in mg/dl (IQR) | 72.5 (37.5) | 93.0 (63.0) | 0.098a |
| C4, median in mg/dl (IQR) | 10.7 (10.2) | 14.2 (10.2) | 0.038a |
| Anti-dsDNA, median in U/ml (IQR) | 33.8 (140.2) | 11.8 (44.5) | 0.097a |
| Antinuclear antibody titer, median−1 (IQR) | 210.0 (280.0) | 320.0 (980.0) | 0.518a |
| APS, n (%) | 4 (33.3) | 6 (17.1) | 0.237b |
| Treatment | |||
| n | 12 | 35 | |
| Prednisone median in mg/day (IQR) | 7.5 (39.4) | 5.0 (10.0) | 0.258a |
| Azathioprine, n (%) | 3 (25.0) | 15 (42.9) | 0.272b |
| Chloroquine, n (%) | 4 (33.3) | 13 (37.1) | 0.813b |
| Cyclophosphamide, n (%) | 2 (16.7) | 2 (5.7) | 0.241b |
IQR, interquartile range; APS, seropositive antiphospholipid syndrome.
aWilcoxon–Mann–Whitney test.
bChi square test.
Bold font indicates p < 0.05.